FDA errs on side of caution in drug approvals (Minneapolis-St. Paul Star Tribune)
TRENTON, N.J. - Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration (FDA) in recent months has rejected a slew of experimental drugs or delayed their approval and required more data. Besides keeping drugs some patients might desperately need off the market, the rejections have battered drug company stock prices and are ...

FDA more cautious on new drug decisions (The Journal News)
Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration in recent months has rejected a slew of experimental drugs or delayed their approval and required more data.